Stroke prevention or bleeding: how to weigh the results of clinical trials

19 March 2018 (16:30 - 16:48)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Professor Lucas Boersma

St Antonius Hospital, Nieuwegein (Netherlands (The))

5 More presentations in this session

Presentation thumbnail

This session is supported by Abbott and Boston Scientific in the form of an educational grant. The scientific programme has not been influenced in any way by these sponsors.

Presentation thumbnail

The role of the LAA for AF and stroke: fact or fiction

Professor T. Lewalter (Munich, DE)

Presentation thumbnail

LAA closure concomitant to AF ablation - The surgical perspective

Associate Professor S. Salzberg (Zurich, CH)

Presentation thumbnail

LAA closure concomitant to AF ablation - The EP perspective

Professor C. Tondo (Milano, IT)

Presentation thumbnail

New strategies for anticoagulation therapy after LAA closure

Professor M. Glikson (Jerusalem, IL)

Access the full session

Session thumbnail

Novel insights of LAA treatment for atrial fibrillation and stroke prevention

The Event

EHRA 2018

19 March 2018 16:30 CET

You may be interested in

Congress Session

Stroke and bleeding risk in atrial fibrillation: walking the tight rope

25 August 2023

Congress Session

The year in review: top trials in coronary interventions impacting guidelines and patient care

1 September 2024

Congress Session

How can targeting FXI(a) advance antithrombotic therapy for stroke prevention?

27 August 2023

Congress Session

Oral anticoagulation in subclinical atrial fibrillation

31 March 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources